Literature DB >> 31342556

Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.

Ali Bukhari1, Firas El Chaer1, Rima Koka2, Zeba Singh2, Elizabeth Hutnick1, Kathleen Ruehle1, Seung Tae Lee1, Mehmet H Kocoglu1, Carl Shanholtz3, Ashraf Badros1, Nancy Hardy1, Jean Yared1, Aaron P Rapoport1, Saurabh Dahiya1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31342556     DOI： 10.1002/ajh.25591

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

1.  Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.

Authors:  John C Bell
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 2.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Frederick L Locke; John M Rossi; Sattva S Neelapu; Caron A Jacobson; David B Miklos; Armin Ghobadi; Olalekan O Oluwole; Patrick M Reagan; Lazaros J Lekakis; Yi Lin; Marika Sherman; Marc Better; William Y Go; Jeffrey S Wiezorek; Allen Xue; Adrian Bot
Journal:  Blood Adv       Date:  2020-10-13

Review 4.  Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.

Authors:  Norihiro Watanabe; Mary Kathryn McKenna; Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

Review 5.  The landscape of bispecific T cell engager in cancer treatment.

Authors:  Shujie Zhou; Mingguo Liu; Fei Ren; Xiangjiao Meng; Jinming Yu
Journal:  Biomark Res       Date:  2021-05-26

Review 6.  Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.

Authors:  Maria Dimou; Aikaterini Bitsani; Wolfgang Bethge; Panayiotis Panayiotidis; Theodoros P Vassilakopoulos
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 7.  New agents and regimens for diffuse large B cell lymphoma.

Authors:  Liang Wang; Lin-Rong Li; Ken H Young
Journal:  J Hematol Oncol       Date:  2020-12-14       Impact factor: 17.388

Review 8.  Engineering enhanced CAR T-cells for improved cancer therapy.

Authors:  Michael C Milone; Jie Xu; Sai-Juan Chen; McKensie A Collins; Jianfeng Zhou; Daniel J Powell; J Joseph Melenhorst
Journal:  Nat Cancer       Date:  2021-08-19

9.  [Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells].

Authors:  S Y Wang; J Cao; K L Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

Review 10.  The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.

Authors:  Dongfang Liu; Saiaditya Badeti; Gianpietro Dotti; Jie-Gen Jiang; He Wang; James Dermody; Patricia Soteropoulos; Deanna Streck; Raymond B Birge; Chen Liu
Journal:  Cell Commun Signal       Date:  2020-08-25       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.